Lexeo Therapeutics, Inc. · NASDAQ:LXEO
Citadel Advisors LLC reported a 9.60% stake in Lexeo Therapeutics, Inc. (Schedule 13G/A)
Event Jun 30, 2025 · Filed Aug 14, 2025
Citadel Advisors LLC reported a 9.60% stake in Lexeo Therapeutics, Inc., 5,325,269 shares, as a passive investor on Jun 30, 2025. Filed Aug 14, 2025 (Schedule 13G/A).
- Stake
- 9.60%
- Shares
- 5,325,269
- Intent
- Passive
- What changed
- Stake changed
- Filed together
- 7 holders
The filing in full
| Holder | Stake | Shares |
|---|---|---|
| Citadel Advisors LLC | 9.60% | 5,325,269 |
| Citadel Advisors Holdings LP | 9.60% | 5,325,269 |
| Citadel GP LLC | 9.60% | 5,325,269 |
| Citadel Securities LLC | 0% | 8,843 |
| Citadel Securities Group LP | 0% | 8,843 |
| Citadel Securities GP LLC | 0% | 8,843 |
| Kenneth Griffin | 9.60% | 5,334,112 |
Source
Related
- Lexeo Therapeutics, Inc.
- Citadel Advisors LLC
- Lexeo Therapeutics, Inc. shareholders
- Schedule 13G/A · Citadel Advisors LLC · Feb 17, 2026
- Schedule 13G · JPMorgan Chase & Co · Oct 13, 2026
- Form 4 · Bhalla Narinder Pal · Sep 28, 2026
- Form 4 · Otero Jose Manuel · Sep 28, 2026
- Form 4 · Townsend Richard Nolan · Sep 28, 2026
- Form 4 · Tamayo Louis Edward · Aug 19, 2026